Pharmaids Pharmaceuticals (524572) Q3 25/26 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 25/26 earnings summary
12 Feb, 2026Executive summary
Unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, were approved by the Board on February 12, 2026.
Both standalone and consolidated results were reviewed by statutory auditors, with no material misstatements identified.
Financial highlights
Standalone revenue from operations for the quarter was Rs. 83.28 lakhs, with a net loss of Rs. 310.98 lakhs.
Consolidated revenue from operations for the quarter was Rs. 543.00 lakhs, with a net loss of Rs. 264.60 lakhs.
For the nine months ended December 31, 2025, standalone revenue was Rs. 596.55 lakhs and consolidated revenue was Rs. 2,069.85 lakhs.
Standalone EPS for the quarter was Rs. (0.88); consolidated EPS was Rs. (0.70).
Outlook and guidance
The company continues to focus on its core segment of Contract Research and Manufacturing Services.
Latest events from Pharmaids Pharmaceuticals
- Q1 FY27 saw a return to profit on exceptional income, despite sharply lower revenue.524572
Q1 26/27 - Revenue increased but net losses persisted; borrowings and cash reserves declined.524572Q4 25/26
- Losses narrowed on higher revenue, with major disinvestment and debt repayment completed.524572Q2 25/26
- Q1 FY26 saw higher losses and a pending major divestment, with no impact on current results.524572Q1 25/26
- Q2 and H1 FY25 results reflect ongoing losses and negative cash flows amid sector focus.524572Q2 24/25
- Losses persist despite higher standalone revenue; consolidated revenue declines year-over-year.524572Q1 24/25
- Revenue growth offset by higher losses and increased investments in FY25.524572Q4 24/25
- Revenue up but losses deepen; asset sale and capital moves mark strategic shift.524572Q3 24/25